Suppr超能文献

新冠疫情期间重症肌无力电话咨询护理:新型虚拟重症肌无力指数评估。

Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: Assessment of a novel virtual myasthenia gravis index.

机构信息

Ellen & Martin Prosserman Centre for Neuromuscular Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada.

出版信息

Muscle Nerve. 2021 Jun;63(6):831-836. doi: 10.1002/mus.27243. Epub 2021 Apr 19.

Abstract

INTRODUCTION/AIMS: The aim of the study was to determine the association between the virtual Myasthenia Gravis Impairment Index (vMGII) with other patient-reported outcomes (PROs) of myasthenia gravis (MG) and its usefulness in telephone consultations with MG patients.

METHODS

This was a retrospective case series in which vMGII score along with virtual Single Simple Question (vSSQ), virtual Patient-Acceptable Symptom State PASS (vPASS) response, and patient disease status based on Myathenia Gravis Foundation of America postintervention status were collected during telephone consultation along with the MGII, SSQ, and PASS responses during the preceding in-person clinic visits.

RESULTS

In 214 patients, the mean difference of vMGII between the vPASS "Yes" and "No" groups was -14.2 ± 1.4 (95% confidence interval, -16.9 to -11.3; P < .001) with mean vMGII for vPASS "Yes" group being 6.4 ± 7.7 and vPASS "No" being 20.5 ± 11.5. A vMGII of 11.5 or higher predicted vPASS "yes" response with a sensitivity of 78.7% and specificity of 81.4%. A strong negative correlation was found between the vMGII and vSSQ (r = -.667; P < .001). The mean vMGII was 0.48 ± 1.42 for patients in remission, and 9.31 ± 10.93 for improved, 9.32 ± 8.79 for stable, and 22.58 ± 14.04 for worsened groups (P < .001). These associations were the same as those obtained during the preceding in-person clinic visit and the direction of change in MGII scores also indicated change in disease status.

DISCUSSION

vMGII is an effective measure to assess an MG patient's disease status in telephone consultations and relates well with other PRO measures. The vMGII remains reliable for assessing MG disease status even with removal of the physical examination component.

摘要

简介/目的:本研究旨在确定虚拟重症肌无力损伤指数(vMGII)与重症肌无力(MG)其他患者报告结局(PRO)之间的关联,以及其在与 MG 患者的电话咨询中的实用性。

方法

这是一项回顾性病例系列研究,在此项研究中,在电话咨询期间收集了 vMGII 评分以及虚拟单简单问题(vSSQ)、虚拟患者可接受症状状态 PASS(vPASS)应答、基于美国重症肌无力基金会干预后状态的患者疾病状态,同时还收集了在之前的门诊就诊期间的 MGII、SSQ 和 PASS 应答。

结果

在 214 例患者中,vPASS“是”和“否”组之间的 vMGII 平均差异为-14.2±1.4(95%置信区间,-16.9 至-11.3;P<0.001),vPASS“是”组的平均 vMGII 为 6.4±7.7,vPASS“否”组为 20.5±11.5。vMGII 为 11.5 或更高可预测 vPASS“是”应答,其敏感性为 78.7%,特异性为 81.4%。vMGII 与 vSSQ 之间存在强烈的负相关(r=-0.667;P<0.001)。缓解组患者的平均 vMGII 为 0.48±1.42,改善组为 9.31±10.93,稳定组为 9.32±8.79,恶化组为 22.58±14.04(P<0.001)。这些关联与之前在门诊就诊时获得的关联相同,并且 MGII 评分的变化方向也表明疾病状态的变化。

讨论

vMGII 是评估电话咨询中 MG 患者疾病状态的有效措施,与其他 PRO 测量方法密切相关。即使没有体检部分,vMGII 仍然可以可靠地评估 MG 疾病状态。

相似文献

2
Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis.
Muscle Nerve. 2022 Nov;66(5):558-561. doi: 10.1002/mus.27657. Epub 2022 Jun 25.
3
Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis.
Eur J Neurol. 2020 Nov;27(11):2286-2291. doi: 10.1111/ene.14397. Epub 2020 Jul 16.
4
Telemedicine visits in myasthenia gravis: Expert guidance and the Myasthenia Gravis Core Exam (MG-CE).
Muscle Nerve. 2021 Sep;64(3):270-276. doi: 10.1002/mus.27260. Epub 2021 Jul 7.
5
Patient-acceptable symptom states in myasthenia gravis.
Neurology. 2020 Sep 22;95(12):e1617-e1628. doi: 10.1212/WNL.0000000000010574. Epub 2020 Aug 5.
6
Time to achieve a patient acceptable symptom state in myasthenia gravis.
Front Neurol. 2023 Jun 16;14:1187189. doi: 10.3389/fneur.2023.1187189. eCollection 2023.
7
Clinical profile and impact of comorbidities in patients with very-late-onset myasthenia gravis.
Muscle Nerve. 2021 Oct;64(4):462-466. doi: 10.1002/mus.27369. Epub 2021 Jul 21.
8
Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis.
Eur J Neurol. 2024 Jan;31(1):e16022. doi: 10.1111/ene.16022. Epub 2023 Aug 16.
9
Myasthenia Gravis Impairment Index: Sensitivity for Change in Generalized Muscle Weakness.
J Neuromuscul Dis. 2020;7(3):297-300. doi: 10.3233/JND-200484.
10
Thymoma pathology and myasthenia gravis outcomes.
Muscle Nerve. 2021 Jun;63(6):868-873. doi: 10.1002/mus.27220. Epub 2021 Mar 16.

引用本文的文献

1
Advocating Patient-Centred Research in Ocular Myasthenia Gravis (OMG): A Call for an OMG Research Consortium.
Front Ophthalmol (Lausanne). 2022 Jul 12;2:912805. doi: 10.3389/fopht.2022.912805. eCollection 2022.
2
Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis.
Ther Adv Rare Dis. 2022 Mar 10;3:26330040221082673. doi: 10.1177/26330040221082673. eCollection 2022 Jan-Dec.
3
Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials.
Neurology. 2023 Sep 5;101(10):442-451. doi: 10.1212/WNL.0000000000207278. Epub 2023 Apr 19.
4
Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.
Neurol Int. 2022 Apr 27;14(2):406-416. doi: 10.3390/neurolint14020033.
5
Development and validation of the Myasthenia Gravis TeleScore (MGTS).
Neurol Sci. 2022 Jul;43(7):4503-4509. doi: 10.1007/s10072-022-05918-y. Epub 2022 Feb 28.

本文引用的文献

1
Patient-acceptable symptom states in myasthenia gravis.
Neurology. 2020 Sep 22;95(12):e1617-e1628. doi: 10.1212/WNL.0000000000010574. Epub 2020 Aug 5.
2
Telemedicine for neuromuscular disorders during the COVID-19 outbreak.
J Neurol. 2021 Jan;268(1):1-4. doi: 10.1007/s00415-020-10063-7. Epub 2020 Jul 10.
3
Comparison of the single simple question and the patient acceptable symptom state in myasthenia gravis.
Eur J Neurol. 2020 Nov;27(11):2286-2291. doi: 10.1111/ene.14397. Epub 2020 Jul 16.
4
Teleneurology during the COVID-19 pandemic: A step forward in modernizing medical care.
J Neurol Sci. 2020 Jul 15;414:116930. doi: 10.1016/j.jns.2020.116930. Epub 2020 May 21.
5
Tackling the Burden of Neurological Diseases in Canada with Virtual Care During the COVID-19 Pandemic and Beyond.
Can J Neurol Sci. 2020 Sep;47(5):594-597. doi: 10.1017/cjn.2020.92. Epub 2020 May 12.
6
Management of neurological care during the COVID-19 pandemic.
Neurologia (Engl Ed). 2020 May;35(4):233-237. doi: 10.1016/j.nrl.2020.04.001. Epub 2020 Apr 10.
7
The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review.
Rheumatol Ther. 2020 Jun;7(2):237-257. doi: 10.1007/s40744-020-00202-x. Epub 2020 Apr 8.
8
Measuring Clinical Treatment Response in Myasthenia Gravis.
Neurol Clin. 2018 May;36(2):339-353. doi: 10.1016/j.ncl.2018.01.006.
9
Myasthenia Gravis Impairment Index: Responsiveness, meaningful change, and relative efficiency.
Neurology. 2017 Dec 5;89(23):2357-2364. doi: 10.1212/WNL.0000000000004676. Epub 2017 Nov 3.
10
The utility of a single simple question in the evaluation of patients with myasthenia gravis.
Muscle Nerve. 2018 Feb;57(2):240-244. doi: 10.1002/mus.25720. Epub 2017 Jun 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验